Clinical trials: Carfilzomib
Multiple Myeloma
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone.
- Trial name
- NCT03290950
- Testing
- daratumumab, carfilzomib, lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.
- Trial name
- NCT04892446
- Testing
- Magrolimab, Daratumumab, Pomalidomide
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to find out what effects carfilzomib has on relapsed multiple myeloma when administered in combination with cyclophosphamide and dexamethasone.
- Trial name
- NCT02597062
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in Canada
- Volunteers
- 76 people
- Sponsor
- Canadian Cancer Trials Group
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's…
- Conditions
- Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00150462
- Testing
- Carfilzomib, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Amgen
Multiple Myeloma
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy…
- Trial name
- NCT01246063
- Testing
- carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Metastatic Castration-resistant Prostate Cancer
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors.
- Trial name
- NCT02047253
- Testing
- Carfilzomib, Dexamethasone, Acyclovir
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Plasmacytoma, Recurrent Multiple Myeloma
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or…
- Conditions
- Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT03031730
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT00963820
- Testing
- Ixazomib citrate
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Background: Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection.
- Trial name
- NCT01572480
- Testing
- Carfilzomib, Revlimid, Dexamethasone
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Advanced Malignancies
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with…
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02265510
- Testing
- INCB052793, gemcitabine, nab-paclitaxel
- Where
- 14 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Neuroendocrine Cancer
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
- Trial name
- NCT02318784
- Testing
- Carfilzomib
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma, Renal Insufficiency
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
- Trial name
- NCT00721734
- Testing
- Carfilzomib
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Relapsed and Refractory Multiple Myeloma
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT00932698
- Testing
- Ixazomib
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma, Leukemia, Plasma Cell
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Background: Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow. It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy with a stem cell transplant.
- Trial name
- NCT01658904
- Testing
- Carfilzomib, Melphalan, Filgrastim
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found.
- Trial name
- MASTER (NCT03224507)
- Testing
- KRdD followed by auto-HCT, KRdD only
- Where
- 4 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Alabama at Birmingham
Hodgkin Disease, Lymphoma, Non-hodgkin
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
This is an open label, phase I/II, dose-escalation study in the initial phase I followed by a phase II. The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the…
- Trial name
- NCT02867618
- Testing
- Carfilzomib, TGR-1202
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Columbia University
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)